The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
XEOMIN Merz Australia Pty Ltd
Product name
XEOMIN
Sponsor
Accepted date
Apr-2024
Active ingredients
incobotulinumtoxinA
Proposed indication
For the treatment of:
• Cervical dystonia (spasmodic torticollis)
• Blepharospasm
• Spasticity of the upper limb
• Spasticity of the lower limb
• Chronic sialorrhea due to neurological disorders
• Upper facial lines
- Glabellar frown lines
- Lateral periorbital lines (crow’s feet)
- Horizontal forehead lines
For the symptomatic treatment of:
• Chronic sialorrhea due to neurological/neurodevelopmental disorders
• Spasticity of the lower and/or upper limbs
• Cervical dystonia (spasmodic torticollis)
• Blepharospasm
• Spasticity of the upper limb
• Spasticity of the lower limb
• Chronic sialorrhea due to neurological disorders
• Upper facial lines
- Glabellar frown lines
- Lateral periorbital lines (crow’s feet)
- Horizontal forehead lines
For the symptomatic treatment of:
• Chronic sialorrhea due to neurological/neurodevelopmental disorders
• Spasticity of the lower and/or upper limbs
Application type
C (new indication)
Publication date
Apr-2024